An observational study in Edema Leg, sponsored by Firstkind Ltd. Completed at 3 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-03-01.
Sponsored by Firstkind Ltd (part of Sky Medical Technology) · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 144 studies in Edema with a site in United States — 23 open to participants now, 27 under way, 4 of them phase 3. Edema · United States.
Among the 144 studies in Edema with a site in United States, this one is the 14th largest by enrollment of the 34 observational ones that give a count, is one of 10 that started in 2021, is one of 34 observational ones, and was the 105th registered.
568 studies on the registry are indexed under Edema; 97 are open to participants now.
Browse Edema studies →23 of the 144 studies in Edema with a site in United States are open now. Recruiting first, the newest first:
St. Jude Children's Research Hospital · Sites in United States
Ages 6–21
Ambros Therapeutics, Inc. · Sites in United States
Ages 18+
University of Washington · Sites in United States
Ages 18+
Stacy Johnson · Sites in United States
Ages 18+
Ambros Therapeutics, Inc. · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 56 Edema studies recruiting now, 34 (61%) set no upper age limit and 16 (29%) stop at 75 or younger; 8 take children under 18; 4 take healthy volunteers.
This study: 18 Years and older · all sexes.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
144 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 24 · Phase 3 16 · Phase 4 14
First in 2000; this study’s year is marked. 10 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 83 is above the median of 66 across 144 observational studies indexed under Edema.
Median enrollment 40 across the 110 interventional studies, 61 across the 34 observational. Of the 97 that completed or were terminated, 40 (41%) have results posted.
This tab as a report to print or save as PDF → With an account.
57 of 144 have an industry lead sponsor. The 10 most frequent:
This study is registered under Firstkind Ltd, one of the names counted as Sky Medical Technology. Under that name alone:
Firstkind Ltd is the lead sponsor of 22 studies on the registry; 2 are open to participants now.
Sky Medical Technology has 4 studies filed under Edema — fewer than ten, so there is no comparison to draw.
13 of the studies in Edema with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06361537Phase 3OctapharmaStudy of IV Human Plasma-derived C1 Esterase Inhibitor Concentrate in Patients With Congenital C1-INH Deficiency for Treatment and Pre-procedure Preventing of Acute Hereditary Angioedema Attacks | 2026-12 |
| NCT04278404Duke UniversityPharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS) | 2026-11 |
| NCT07178470Indiana UniversityConcordance and Discordance in the Assessment of Volume Status in Home Dialysis Patients: A Comparison of Modified Medical Research Council Dyspnea Scale, Physical Exam, and Point of Care Ultrasound (POCUS) | 2026-11-30 |
| NCT06979726University of FloridaGator SCALES-WHF: SubCutaneous Administration of Lasix to Eliminate Symptoms of Worsening Heart Failure | 2026-11-30 |
| NCT06823115Indiana UniversityAssessment of Worldwide Acute Kidney Injury Epidemiology in Neonates 2.0 | 2027-01 |
Add all 13 to your calendar (.ics) → With an account.
Among the 144 studies in Edema with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The geko™ Cross Therapy Registry - Edema (gekoTM CTR - Edema) study will prospectively and systematically collect clinical data on all device variants used in standard care pathways for edema management allowing for the monitoring of patient outcomes during a follow-up period of up to twelve months.
The geko™ device has a wide range of clinical applications including the post-operative management of edema.
Although many short-term acute studies have been completed using the device, little clinical data has been collected on the effect of geko™ use in current standard care pathways for edema management on patient outcomes during follow-up of up to twelve months.
As the manufacturer of the device, Firstkind Limited has an obligation to collect safety and performance data to comply with current regulations (MDR EU 2017/745 Annex XIV, Part B). Consequently, there is a need for an observational study to provide data to demonstrate patient benefit and regulatory compliance.
The geko™ Cross Therapy Registry - Edema (gekoTM CTR - Edema) study will prospectively and systematically collect clinical data on all device variants used in standard care pathways for edema management allowing for the monitoring of patient outcomes during a follow-up period of up to twelve months. This study forms part of the overall Post-Market Clinical Follow-up strategy for the device and Post Market Surveillance (PMS) to support device and performance.
Participants who have been identified to receive gekoTM therapy as part of their standard care for edema reduction.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Neuromuscular Electro Stimulator (NMES)
Safety
Safety: determine frequency of adverse events (AEs) and serious AEs (SAEs) whether device related or not and compare rate to historic and published data i.e. gekoTM vs standard of care (SC).
Time frame: One year
Performance
Performance: determine frequency of Device Deficiencies (DD) and compare rate to historic and published data i.e. gekoTM vs SC.
Time frame: One year
Summary of routinely collected performance data
Summarize routinely tested and collected performance data, such as patient reported outcome measures and compare to historic and published data i.e. gekoTM vs SC.
Time frame: One Year
Summary of Health Economic Impact
Summarize health economic impact of gekoTM device on patient outcomes in comparison to SC.
Time frame: One year
Plan to share: No
Ran from Jun 2021 to primary completion in Aug 2023, 26 months.
Of 85 observational studies under Edema, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 47. This study's 26 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.